Most Read News

Revenue for the quarter rose by 4.1% year-on-year to ₹3,052 Crore, up from ₹2,931.3 Crore in Q2 FY24.

Lupin ranks as the third-largest pharmaceutical player in the U.S. by prescriptions and seventh in the Indian Pharmaceutical Market (IPM).

Jerome Powell has refused to allow political calculations to impact the thinking of the Fed on the rates trajectory

Chhatwal stated that he is "confident" of the forecast after examining the chain's previous ten quarters

Not only did LIC lag private insurers in NBP, but it also saw the number of policies sold falling precipitously

FPIs sold $2.37 Billion in Indian equities in the latest week, taking FPI selling in stocks in last 5 weeks to $13.6 Billion

Friday's retail sales and industrial output reports should demonstrate whether Beijing's multiple stimulus initiatives are indeed impacting demand.

EBITDA margin slightly declined, down 80 basis points to 20.8% in Q2, reflecting some operational pressures.

Find out how equity and preference shares differ from each other and their types to understand how this factor influences.

Yasushi Itagaki, head of MUFG's worldwide commercial banking unit, stated in an interview that the company's objective is to boost its buyouts and investments in India